NCT05685004 — TVAX Biomedical neoantigen vaccine trial
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Registry record
| Registry ID | NCT05685004 ↗ |
|---|---|
| Lead sponsor | TVAX Biomedical |
| Collaborators | — |
| Phase | Phase 2/3 |
| Status | Active Not Recruiting |
| Indication | Glioblastoma Multiforme of Brain |
| Enrollment | 120 participants (target) |
| Start date | 2023-12-27 |
| Primary completion | 2030-11 (est.) |
| Last registry update | 29 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05685004), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05685004?
NCT05685004 (Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)) is registered on ClinicalTrials.gov as Phase 2/3, sponsored by TVAX Biomedical.
Is NCT05685004 recruiting?
As of the 2026-09-29 registry update, NCT05685004 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05685004?
The lead sponsor is TVAX Biomedical.
What condition does NCT05685004 study?
The registered condition is Glioblastoma Multiforme of Brain. Primary completion is listed as 2030-11 (estimated).
Are results available for NCT05685004?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05685004.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.